Gadolinium-based contrast agents (GBCAs) are fundamental to many diagnostic MRI procedures. However, until recently, most purely extracellular GBCAs had similar relaxivity properties resulting in similar contrast enhancement when administered at equivalent dose. Gadopiclenol is a newly approved, highly stable GBCA with markedly increased relaxivity which permits the administered dose to be halved relative to the approved dose of most other extracellular GBCAs without loss of diagnostic performance. This symposium will address the importance of high relaxivity in clinical practice and will present early clinical experience with gadopiclenol for approved indications in the body and CNS.
Introduction
Carlo Catalano, Roma / Italy
The clinical value of high relaxivity
Josef Vymazal, Prague / Czechia
To appreciate the value of high relaxivity MR contrast agents in clinical practice.
Implementation of Gadopiclenol as the extracellular agent for Body MRI Applications
Ali Pirasteh, Madison / United States
To learn about the benefits of the newly approved MR contrast agent gadopiclenol for body applications.
Experience with Gadopiclenol for MRI of the CNS.
Emanuel Kanal, Pittsburgh / United States
To learn about the benefits of the newly approved MR contrast agent gadopiclenol for MRI of the CNS.